Clinical trials: Healthy Patients
Diabetes Mellitus, Type 2
A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes
The main purpose of this study is to determine the safety of LY2409021 in healthy participants and participants with diabetes. The study drug is given as single oral doses.
- Trial name
- NCT01606371
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Psoriasis
A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis
The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis.
- Trial name
- NCT03418493
- Testing
- LY3316531 - IV, LY3316531 - SC
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Ulcerative Colitis (UC)
Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics (PK) of ATTO-1091 in healthy adults and patients with ulcerative colitis.
- Trial name
- NCT07819799
- Testing
- ATTO-1091
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Healthy Volunteers, Relapsed Multiple Myeloma
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
- Conditions
- Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07342114
- Testing
- RO7875913, Cevostamab
- Where
- New Zealand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy Volunteers, Hepatitis C Virus
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
This is an adaptive Phase I study to evaluate RO5024048 in the following groups: Healthy Volunteers (Part 1 - Single Ascending Dose Study) -Enrollment completed Hepatitis C virus (HCV) genotype 1 infected patients who have failed…
- Trial name
- R7128 (NCT00382798)
- Testing
- RO5024048
- Where
- 9 sites in United States, New Zealand and 1 more
- Volunteers
- 75 people
- Sponsor
- Pharmasset
NASH - Nonalcoholic Steatohepatitis, Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
This is a single centre, open label, randomized, 3 treatment arms, with and without food dosing, Phase 1b pharmacology study to assess the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Farnesoid X…
- Trial name
- NCT03976687
- Testing
- EYP001a
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Psoriasis
Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in healthy adults and patients with mild to moderate psoriasis.
- Trial name
- NCT02574091
- Testing
- 1% icotinib hydrochloride cream, 2% icotinib hydrochloride cream
- Where
- New Zealand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Open Angle Glaucoma, Ocular Hypertension
A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension
This is a Phase I/II stage to investigate the safety, tolerability, and ocular hypotensive efficacy of TO-O-1001 in healthy volunteers and patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT05456724
- Testing
- TO-O-1001
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Theratocular Biotek Co.
Circulating Tumor Cells (CTCs)
Detection of Circulating Tumor Cells in Peripheral Blood From Healthy Volunteers and Patients With Cancer
To address the challenges of isolating and analyzing rare cells, this study aims to validate technical diagnostic instrumentation, tests, protocols and analysis to correlate the number of circulating tumor cells present in whole…
- Trial name
- NCT02904161
- Where
- Taiwan
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- MiCareo Taiwan Co., Ltd.
Dyslipidemia
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)
This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.
- Trial name
- NCT00111891
- Testing
- niacin (+) laropiprant
- Volunteers
- 575 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Renal Impairment
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers
The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in renal impairment patients and healthy volunteers.
- Trial name
- NCT01148368
- Testing
- fimasartan
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Ocular Hypertension, Open-Angle Glaucoma
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
- Trial name
- NCT02743780
- Testing
- MGV354 ophthalmic suspension
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Immune-Mediated Inflammatory Disease
Digital Health Program With Participants Using an Autoinjector
This is a prospective, single-arm, feasibility study. Up to thirty (30) participants meeting study eligibility criteria will use the SK-M11/3A1 digital health program for 12 weeks.
- Trial name
- NCT06112184
- Testing
- SK-M11/3A1 Digital health program
- Where
- Iceland
- Volunteers
- 27 people
- Sponsor
- Sidekick Health
Influenza
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms
This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with…
- Trial name
- NCT03629184
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- 37 sites in United States, Costa Rica and 5 more
- Volunteers
- 173 people
- Sponsor
- Hoffmann-La Roche
Healthy, Chronic Rhinosinusitis With Nasal Polyps
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06817024 in healthy volunteers, in participants with chronic rhinosinusitis, with nasal polyps and in participants with…
- Conditions
- Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
- Trial name
- NCT02743871
- Testing
- PF-06817024
- Where
- 20 sites in United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
COPD, Asthma
Cardiorespiratory Diagnostic Study
This study uses a new breathing device called 'N-Tidal C' handset which measures breathing patterns. Investigators have found that people with cardiac and respiratory illnesses breathe out a gas, called carbon dioxide (CO2), in a…
- Conditions
- COPD, Asthma, Lung Cancer, Anemia
- Trial name
- CARES (NCT04939558)
- Testing
- N-Tidal C handset
- Where
- United Kingdom
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- TidalSense
Healthy Subjects, Cystic Fibrosis
A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
This Phase 1/2a study is a double-blinded (subject and Investigator), randomized, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple…
- Trial name
- NCT03647228
- Testing
- IONIS-ENaCRx
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Psoriasis
Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.
The purpose of this study is to assess the local tolerability of a single topical administration of BCT194 in healthy volunteers and, potentially, to evaluate the safety, tolerability, and efficacy of a multiple topical…
- Trial name
- NCT00417820
- Testing
- BCT194
- Where
- Austria
- Volunteers
- 35 people
- Sponsor
- Novartis
Kidney Failure, Chronic
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A phase I, open-label study comparing the pharmacokinetics, pharmacodynamics, safety and tolerability of ticagrelor in hemodialysis patients to healthy subjects with normal renal function.
- Trial name
- NCT02022748
- Testing
- ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca